Semaglutide 2.4 mg reduces the 10-year type 2 diabetes risk in people with overweight or obesity - report from EASD2022 episode artwork

EPISODE · Oct 11, 2022 · 10 MIN

Semaglutide 2.4 mg reduces the 10-year type 2 diabetes risk in people with overweight or obesity - report from EASD2022

from Medical Digest & Congress Report · host Medical Congress News

Professor Timothy Garvey, Director of Diabetes Research Center at University of Alabama presented new data from the STEP trial program at this year EASD Congress in Stockholm. Video: https://congressreport.eu/scientific-contents/interview:semaglutide-24-mg-reduces-10-year-type-2-diabetes-risk-people-overweight-or-obesity

Episode metadata supplied by the publisher feed · Published Oct 11, 2022

Embed this episode

Ready to play

Semaglutide 2.4 mg reduces the 10-year type 2 diabetes risk in people with overweight or obesity - report from EASD2022

0:00 10:58

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of Medical Digest & Congress Report?

This episode is 10 minutes long.

When was this Medical Digest & Congress Report episode published?

This episode was published on October 11, 2022.

Can I download this Medical Digest & Congress Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!